Based V2 is now live, optimized for performance and reliability

Roivant Sciences Ltd. (ROIV) announced that its board of directors has officially approved a stock buyback plan totaling up to 1 billion dollars.

Vertiv (Vertiv Holdings LLC) recently announced the successful completion of two key financing transactions: a $2.1 billion senior unsecured bond issuance and a $2.5 billion senior unsecured revolving credit facility.

The biopharmaceutical company Arbutus Biopharma Corporation (ABUS), a subsidiary of Roivant Sciences Ltd. (ROIV), is currently actively evaluating a capital return plan.

According to the settlement agreement, Genevant Sciences, a subsidiary of Roivant Sciences Ltd., will grant Moderna, Inc. a non-exclusive license allowing the use of its lipid nanoparticle delivery technology for applications in the field of infectious diseases.